ID   DHSO_HUMAN              Reviewed;         357 AA.
AC   Q00796; B2R655; B7Z3A6; J3JZZ5; Q16682; Q9UMD6;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-MAR-2010, sequence version 4.
DT   03-AUG-2022, entry version 222.
DE   RecName: Full=Sorbitol dehydrogenase {ECO:0000303|PubMed:12962626, ECO:0000303|PubMed:3365415, ECO:0000303|PubMed:8088829};
DE            Short=SDH {ECO:0000303|PubMed:12962626};
DE            EC=1.1.1.- {ECO:0000269|PubMed:12962626, ECO:0000269|PubMed:3365415};
DE   AltName: Full=(R,R)-butanediol dehydrogenase {ECO:0000305|PubMed:3365415};
DE            EC=1.1.1.4 {ECO:0000269|PubMed:3365415};
DE   AltName: Full=L-iditol 2-dehydrogenase;
DE            EC=1.1.1.14 {ECO:0000250|UniProtKB:P07846};
DE   AltName: Full=Polyol dehydrogenase {ECO:0000303|PubMed:3365415};
DE   AltName: Full=Ribitol dehydrogenase {ECO:0000305|PubMed:3365415};
DE            Short=RDH;
DE            EC=1.1.1.56 {ECO:0000269|PubMed:3365415};
DE   AltName: Full=Xylitol dehydrogenase {ECO:0000303|PubMed:3365415};
DE            Short=XDH;
DE            EC=1.1.1.9 {ECO:0000269|PubMed:3365415};
GN   Name=SORD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-269.
RC   TISSUE=Liver;
RX   PubMed=8088829; DOI=10.1006/geno.1994.1276;
RA   Lee F.K., Cheung M.C., Chung S.;
RT   "The human sorbitol dehydrogenase gene: cDNA cloning, sequence
RT   determination, and mapping by fluorescence in situ hybridization.";
RL   Genomics 21:354-358(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANTS LEU-239
RP   AND THR-269.
RX   PubMed=7782086; DOI=10.1016/0888-7543(95)80082-w;
RA   Iwata T., Popescu N.C., Zimonjic D.B., Karlsson C., Hoeoeg J.-O., Vaca G.,
RA   Rodriguez I.R., Carper D.;
RT   "Structural organization of the human sorbitol dehydrogenase gene (SORD).";
RL   Genomics 26:55-62(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-269.
RX   PubMed=9183016; DOI=10.1111/j.1432-1033.1997.00760.x;
RA   Carr I.M., Markham A.F., Coletta P.L.;
RT   "Identification and characterisation of a sequence related to human
RT   sorbitol dehydrogenase.";
RL   Eur. J. Biochem. 245:760-767(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   THR-269.
RC   TISSUE=Brain, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-269.
RC   TISSUE=Brain, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-357.
RC   TISSUE=Liver;
RX   PubMed=2691249; DOI=10.1111/j.1432-1033.1989.tb15240.x;
RA   Karlsson C., Maret W., Auld D.S., Hoeoeg J.-O., Joernvall H.;
RT   "Variability within mammalian sorbitol dehydrogenases. The primary
RT   structure of the human liver enzyme.";
RL   Eur. J. Biochem. 186:543-550(1989).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-21.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, COFACTOR, ACTIVITY REGULATION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=3365415; DOI=10.1021/bi00405a035;
RA   Maret W., Auld D.S.;
RT   "Purification and characterization of human liver sorbitol dehydrogenase.";
RL   Biochemistry 27:1622-1628(1988).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16278369; DOI=10.2164/jandrol.05108;
RA   Frenette G., Thabet M., Sullivan R.;
RT   "Polyol pathway in human epididymis and semen.";
RL   J. Androl. 27:233-239(2006).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=20372835; DOI=10.3892/or_00000755;
RA   Szabo Z., Hamalainen J., Loikkanen I., Moilanen A.M., Hirvikoski P.,
RA   Vaisanen T., Paavonen T.K., Vaarala M.H.;
RT   "Sorbitol dehydrogenase expression is regulated by androgens in the human
RT   prostate.";
RL   Oncol. Rep. 23:1233-1239(2010).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=19423711; DOI=10.1074/jbc.m109.001792;
RA   Lanaspa M.A., Andres-Hernando A., Rivard C.J., Dai Y., Li N., Berl T.;
RT   "ZAC1 is up-regulated by hypertonicity and decreases sorbitol dehydrogenase
RT   expression, allowing accumulation of sorbitol in kidney cells.";
RL   J. Biol. Chem. 284:19974-19981(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   REVIEW, AND ROLE OF THE POLYOL PATHWAY IN DIABETIC RETINOPATHY.
RX   PubMed=25105142; DOI=10.1155/2014/801269;
RA   Safi S.Z., Qvist R., Kumar S., Batumalaie K., Ismail I.S.;
RT   "Molecular mechanisms of diabetic retinopathy, general preventive
RT   strategies, and novel therapeutic targets.";
RL   Biomed. Res. Int. 2014:801269-801269(2014).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-211 AND SER-225, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   REVIEW, AND ROLE OF THE POLYOL PATHWAY IN DIABETIC NEUROPATHY.
RX   PubMed=29966615; DOI=10.1016/j.ejphar.2018.06.034;
RA   Dewanjee S., Das S., Das A.K., Bhattacharjee N., Dihingia A., Dua T.K.,
RA   Kalita J., Manna P.;
RT   "Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic
RT   targets.";
RL   Eur. J. Pharmacol. 833:472-523(2018).
RN   [19] {ECO:0007744|PDB:1PL6, ECO:0007744|PDB:1PL7, ECO:0007744|PDB:1PL8}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEXES WITH ZINC; NAD AND
RP   INHIBITOR CP-166,572, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, ACTIVITY REGULATION, SUBUNIT, AND REACTION MECHANISM.
RX   PubMed=12962626; DOI=10.1016/s0969-2126(03)00167-9;
RA   Pauly T.A., Ekstrom J.L., Beebe D.A., Chrunyk B., Cunningham D.,
RA   Griffor M., Kamath A., Lee S.E., Madura R., Mcguire D., Subashi T.,
RA   Wasilko D., Watts P., Mylari B.L., Oates P.J., Adams P.D., Rath V.L.;
RT   "X-ray crystallographic and kinetic studies of human sorbitol
RT   dehydrogenase.";
RL   Structure 11:1071-1085(2003).
RN   [20]
RP   VARIANTS SORDD PHE-10; 100-ARG--PRO-357 DEL; PRO-110; ASP-153;
RP   299-ARG--PRO-357 DEL AND ILE-322, AND INVOLVEMENT IN SORDD.
RX   PubMed=32367058; DOI=10.1038/s41588-020-0615-4;
RG   Inherited Neuropathy Consortium;
RA   Cortese A., Zhu Y., Rebelo A.P., Negri S., Courel S., Abreu L., Bacon C.J.,
RA   Bai Y., Bis-Brewer D.M., Bugiardini E., Buglo E., Danzi M.C., Feely S.M.E.,
RA   Athanasiou-Fragkouli A., Haridy N.A., Isasi R., Khan A., Laura M.,
RA   Magri S., Pipis M., Pisciotta C., Powell E., Rossor A.M., Saveri P.,
RA   Sowden J.E., Tozza S., Vandrovcova J., Dallman J., Grignani E.,
RA   Marchioni E., Scherer S.S., Tang B., Lin Z., Al-Ajmi A., Schuele R.,
RA   Synofzik M., Maisonobe T., Stojkovic T., Auer-Grumbach M., Abdelhamed M.A.,
RA   Hamed S.A., Zhang R., Manganelli F., Santoro L., Taroni F., Pareyson D.,
RA   Houlden H., Herrmann D.N., Reilly M.M., Shy M.E., Zhai R.G., Zuchner S.;
RT   "Biallelic mutations in SORD cause a common and potentially treatable
RT   hereditary neuropathy with implications for diabetes.";
RL   Nat. Genet. 52:473-481(2020).
RN   [21]
RP   ERRATUM.
RX   PubMed=32457452; DOI=10.1038/s41588-020-0649-7;
RG   Inherited Neuropathy Consortium;
RA   Cortese A., Zhu Y., Rebelo A.P., Negri S., Courel S., Abreu L., Bacon C.J.,
RA   Bai Y., Bis-Brewer D.M., Bugiardini E., Buglo E., Danzi M.C., Feely S.M.E.,
RA   Athanasiou-Fragkouli A., Haridy N.A., Isasi R., Khan A., Laura M.,
RA   Magri S., Pipis M., Pisciotta C., Powell E., Rossor A.M., Saveri P.,
RA   Sowden J.E., Tozza S., Vandrovcova J., Dallman J., Grignani E.,
RA   Marchioni E., Scherer S.S., Tang B., Lin Z., Al-Ajmi A., Schuele R.,
RA   Synofzik M., Maisonobe T., Stojkovic T., Auer-Grumbach M., Abdelhamed M.A.,
RA   Hamed S.A., Zhang R., Manganelli F., Santoro L., Taroni F., Pareyson D.,
RA   Houlden H., Herrmann D.N., Reilly M.M., Shy M.E., Zhai R.G., Zuchner S.;
RL   Nat. Genet. 52:640-640(2020).
RN   [22]
RP   VARIANT SORDD 209-ARG--PRO-357 DEL, AND INVOLVEMENT IN SORDD.
RX   PubMed=33314640; DOI=10.1002/acn3.51268;
RA   Yuan R.Y., Ye Z.L., Zhang X.R., Xu L.Q., He J.;
RT   "Evaluation of SORD mutations as a novel cause of Charcot-Marie-Tooth
RT   disease.";
RL   Ann. Clin. Transl. Neurol. 8:266-270(2021).
RN   [23]
RP   VARIANT SORDD ARG-135, AND CHARACTERIZATION OF VARIANTS SORDD PRO-110;
RP   ARG-135 AND ASP-153.
RX   PubMed=33397963; DOI=10.1038/s41525-020-00165-6;
RA   Dong H.L., Li J.Q., Liu G.L., Yu H., Wu Z.Y.;
RT   "Biallelic SORD pathogenic variants cause Chinese patients with distal
RT   hereditary motor neuropathy.";
RL   NPJ Genom. Med. 6:1-1(2021).
CC   -!- FUNCTION: Polyol dehydrogenase that catalyzes the reversible NAD(+)-
CC       dependent oxidation of various sugar alcohols. Is mostly active with D-
CC       sorbitol (D-glucitol), L-threitol, xylitol and ribitol as substrates,
CC       leading to the C2-oxidized products D-fructose, L-erythrulose, D-
CC       xylulose, and D-ribulose, respectively (PubMed:3365415). Is a key
CC       enzyme in the polyol pathway that interconverts glucose and fructose
CC       via sorbitol, which constitutes an important alternate route for
CC       glucose metabolism. The polyol pathway is believed to be involved in
CC       the etiology of diabetic complications, such as diabetic neuropathy and
CC       retinopathy, induced by hyperglycemia (PubMed:12962626,
CC       PubMed:29966615, PubMed:25105142). May play a role in sperm motility by
CC       using sorbitol as an alternative energy source for sperm motility
CC       (PubMed:16278369). May have a more general function in the metabolism
CC       of secondary alcohols since it also catalyzes the stereospecific
CC       oxidation of (2R,3R)-2,3-butanediol. To a lesser extent, can also
CC       oxidize L-arabinitol, galactitol and D-mannitol and glycerol in vitro.
CC       Oxidizes neither ethanol nor other primary alcohols. Cannot use NADP(+)
CC       as the electron acceptor (PubMed:3365415).
CC       {ECO:0000269|PubMed:16278369, ECO:0000269|PubMed:3365415,
CC       ECO:0000303|PubMed:25105142, ECO:0000303|PubMed:29966615,
CC       ECO:0000305|PubMed:12962626}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + keto-D-fructose + NADH = D-sorbitol + NAD(+);
CC         Xref=Rhea:RHEA:33031, ChEBI:CHEBI:15378, ChEBI:CHEBI:17924,
CC         ChEBI:CHEBI:48095, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         Evidence={ECO:0000269|PubMed:12962626, ECO:0000269|PubMed:3365415};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:33033;
CC         Evidence={ECO:0000305|PubMed:12962626};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threitol + NAD(+) = H(+) + L-erythrulose + NADH;
CC         Xref=Rhea:RHEA:48760, ChEBI:CHEBI:15378, ChEBI:CHEBI:27913,
CC         ChEBI:CHEBI:42090, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         Evidence={ECO:0000269|PubMed:3365415};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NAD(+) + xylitol = D-xylulose + H(+) + NADH;
CC         Xref=Rhea:RHEA:20433, ChEBI:CHEBI:15378, ChEBI:CHEBI:17140,
CC         ChEBI:CHEBI:17151, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.9;
CC         Evidence={ECO:0000269|PubMed:3365415};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NAD(+) + ribitol = D-ribulose + H(+) + NADH;
CC         Xref=Rhea:RHEA:20053, ChEBI:CHEBI:15378, ChEBI:CHEBI:15963,
CC         ChEBI:CHEBI:17173, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.56;
CC         Evidence={ECO:0000269|PubMed:3365415};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R,R)-butane-2,3-diol + NAD(+) = (R)-acetoin + H(+) + NADH;
CC         Xref=Rhea:RHEA:24340, ChEBI:CHEBI:15378, ChEBI:CHEBI:15686,
CC         ChEBI:CHEBI:16982, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.4;
CC         Evidence={ECO:0000269|PubMed:3365415};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-iditol + NAD(+) = H(+) + keto-L-sorbose + NADH;
CC         Xref=Rhea:RHEA:10160, ChEBI:CHEBI:13172, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:18202, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.14;
CC         Evidence={ECO:0000250|UniProtKB:P07846};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:12962626, ECO:0000269|PubMed:3365415};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:12962626,
CC       ECO:0000269|PubMed:3365415};
CC   -!- ACTIVITY REGULATION: Inhibited by CP-166,572, an inhibitor that is
CC       competitive with fructose (PubMed:12962626). Also competitively
CC       inhibited by phenanthroline and 4-methylpyrazole in vitro
CC       (PubMed:3365415). {ECO:0000269|PubMed:12962626,
CC       ECO:0000269|PubMed:3365415}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.5 mM for sorbitol {ECO:0000269|PubMed:12962626};
CC         KM=225 uM for NAD(+) {ECO:0000269|PubMed:12962626};
CC         KM=210 uM for NADH {ECO:0000269|PubMed:12962626};
CC         KM=0.62 mM for D-sorbitol (at pH 7.1) {ECO:0000269|PubMed:3365415};
CC         KM=0.67 mM for D-sorbitol (at pH 10.0) {ECO:0000269|PubMed:3365415};
CC         KM=0.22 mM for xylitol (at pH 10.0) {ECO:0000269|PubMed:3365415};
CC         KM=2.7 mM for L-threitol (at pH 10.0) {ECO:0000269|PubMed:3365415};
CC         KM=9.5 mM for (2R,3R)-2,3-butanediol (at pH 10.0)
CC         {ECO:0000269|PubMed:3365415};
CC         KM=0.14 M for D-fructose (at pH 7.1) {ECO:0000269|PubMed:3365415};
CC         Note=kcat is 1.7 sec(-1) for the oxidation of D-sorbitol at pH 7.1,
CC         and 5.2 sec(-1) at pH 10.0. kcat is 5.9 sec(-1) the oxidation of
CC         xylitol as substrate at pH 10.0. kcat is 5.3 sec(-1) the oxidation of
CC         L-threitol as substrate at pH 10.0. kcat is 4.2 sec(-1) the oxidation
CC         of (2R,3R)-2,3-butanediol as substrate at pH 10.0. kcat is 45 sec(-1)
CC         for the reduction of D-fructose at pH 7.1.
CC         {ECO:0000269|PubMed:3365415};
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:12962626,
CC       ECO:0000269|PubMed:3365415}.
CC   -!- INTERACTION:
CC       Q00796; Q00796: SORD; NbExp=6; IntAct=EBI-750068, EBI-750068;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion membrane
CC       {ECO:0000250|UniProtKB:Q64442}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q64442}. Cell projection, cilium, flagellum
CC       {ECO:0000250|UniProtKB:Q64442}. Note=Associated with mitochondria of
CC       the midpiece and near the plasma membrane in the principal piece of the
CC       flagellum. Also found in the epididymosome, secreted by the epididymal
CC       epithelium and that transfers proteins from the epididymal fluid to the
CC       sperm surface. {ECO:0000250|UniProtKB:Q64442}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q00796-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q00796-2; Sequence=VSP_056353, VSP_056354;
CC   -!- TISSUE SPECIFICITY: Expressed in liver (PubMed:3365415). Expressed in
CC       kidney and epithelial cells of both benign and malignant prostate
CC       tissue. Expressed in epididymis (at protein level).
CC       {ECO:0000269|PubMed:16278369, ECO:0000269|PubMed:19423711,
CC       ECO:0000269|PubMed:20372835, ECO:0000269|PubMed:3365415}.
CC   -!- INDUCTION: Up-regulated by androgens and down-regulated by castration.
CC       {ECO:0000269|PubMed:20372835}.
CC   -!- DISEASE: Sorbitol dehydrogenase deficiency with peripheral neuropathy
CC       (SORDD) [MIM:618912]: An autosomal recessive disorder characterized by
CC       motor axonal neuropathy, slowly progressive distal muscle weakness
CC       mainly affecting the lower limbs, difficulty walking, and increased
CC       serum sorbitol. Additional variable features are distal sensory
CC       impairment, upper limb tremor, scoliosis, and mild hearing loss.
CC       {ECO:0000269|PubMed:32367058, ECO:0000269|PubMed:33314640,
CC       ECO:0000269|PubMed:33397963}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the zinc-containing alcohol dehydrogenase
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U07361; AAA66064.1; -; mRNA.
DR   EMBL; L29008; AAA80565.1; -; mRNA.
DR   EMBL; L29254; AAA80566.1; -; Genomic_DNA.
DR   EMBL; L29249; AAA80566.1; JOINED; Genomic_DNA.
DR   EMBL; L29250; AAA80566.1; JOINED; Genomic_DNA.
DR   EMBL; L29251; AAA80566.1; JOINED; Genomic_DNA.
DR   EMBL; L29252; AAA80566.1; JOINED; Genomic_DNA.
DR   EMBL; L29253; AAA80566.1; JOINED; Genomic_DNA.
DR   EMBL; U67243; AAB61898.1; -; Genomic_DNA.
DR   EMBL; U67236; AAB61898.1; JOINED; Genomic_DNA.
DR   EMBL; U67237; AAB61898.1; JOINED; Genomic_DNA.
DR   EMBL; U67238; AAB61898.1; JOINED; Genomic_DNA.
DR   EMBL; U67239; AAB61898.1; JOINED; Genomic_DNA.
DR   EMBL; U67240; AAB61898.1; JOINED; Genomic_DNA.
DR   EMBL; U67241; AAB61898.1; JOINED; Genomic_DNA.
DR   EMBL; U67242; AAB61898.1; JOINED; Genomic_DNA.
DR   EMBL; AK295656; BAH12142.1; -; mRNA.
DR   EMBL; AK312444; BAG35352.1; -; mRNA.
DR   EMBL; AC090888; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091117; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC021085; AAH21085.1; -; mRNA.
DR   EMBL; BC025295; AAH25295.1; -; mRNA.
DR   CCDS; CCDS10116.1; -. [Q00796-1]
DR   PIR; A54674; A54674.
DR   RefSeq; NP_003095.2; NM_003104.5. [Q00796-1]
DR   PDB; 1PL6; X-ray; 2.00 A; A/B/C/D=2-357.
DR   PDB; 1PL7; X-ray; 2.20 A; A/B/C/D=2-357.
DR   PDB; 1PL8; X-ray; 1.90 A; A/B/C/D=2-357.
DR   PDBsum; 1PL6; -.
DR   PDBsum; 1PL7; -.
DR   PDBsum; 1PL8; -.
DR   AlphaFoldDB; Q00796; -.
DR   SMR; Q00796; -.
DR   BioGRID; 112535; 88.
DR   IntAct; Q00796; 15.
DR   MINT; Q00796; -.
DR   STRING; 9606.ENSP00000267814; -.
DR   BindingDB; Q00796; -.
DR   ChEMBL; CHEMBL2275; -.
DR   DrugBank; DB04478; Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-Pyrimidine.
DR   DrugBank; DB00157; NADH.
DR   DrugCentral; Q00796; -.
DR   iPTMnet; Q00796; -.
DR   MetOSite; Q00796; -.
DR   PhosphoSitePlus; Q00796; -.
DR   SwissPalm; Q00796; -.
DR   BioMuta; SORD; -.
DR   DMDM; 292495088; -.
DR   REPRODUCTION-2DPAGE; IPI00216057; -.
DR   EPD; Q00796; -.
DR   jPOST; Q00796; -.
DR   MassIVE; Q00796; -.
DR   MaxQB; Q00796; -.
DR   PaxDb; Q00796; -.
DR   PeptideAtlas; Q00796; -.
DR   PRIDE; Q00796; -.
DR   ProteomicsDB; 57873; -. [Q00796-1]
DR   ProteomicsDB; 6501; -.
DR   Antibodypedia; 24307; 573 antibodies from 32 providers.
DR   DNASU; 6652; -.
DR   Ensembl; ENST00000267814.14; ENSP00000267814.9; ENSG00000140263.15. [Q00796-1]
DR   Ensembl; ENST00000558789.5; ENSP00000453904.1; ENSG00000140263.15. [Q00796-2]
DR   GeneID; 6652; -.
DR   KEGG; hsa:6652; -.
DR   MANE-Select; ENST00000267814.14; ENSP00000267814.9; NM_003104.6; NP_003095.2.
DR   UCSC; uc001zul.5; human. [Q00796-1]
DR   CTD; 6652; -.
DR   DisGeNET; 6652; -.
DR   GeneCards; SORD; -.
DR   HGNC; HGNC:11184; SORD.
DR   HPA; ENSG00000140263; Tissue enhanced (cervix, liver).
DR   MalaCards; SORD; -.
DR   MIM; 182500; gene.
DR   MIM; 618912; phenotype.
DR   neXtProt; NX_Q00796; -.
DR   OpenTargets; ENSG00000140263; -.
DR   PharmGKB; PA36021; -.
DR   VEuPathDB; HostDB:ENSG00000140263; -.
DR   eggNOG; KOG0024; Eukaryota.
DR   GeneTree; ENSGT00550000074781; -.
DR   HOGENOM; CLU_168382_0_0_1; -.
DR   InParanoid; Q00796; -.
DR   OMA; ETWYAMS; -.
DR   OrthoDB; 1019156at2759; -.
DR   PhylomeDB; Q00796; -.
DR   TreeFam; TF313060; -.
DR   BRENDA; 1.1.1.14; 2681.
DR   PathwayCommons; Q00796; -.
DR   Reactome; R-HSA-5652227; Fructose biosynthesis.
DR   Reactome; R-HSA-5661270; Formation of xylulose-5-phosphate.
DR   SABIO-RK; Q00796; -.
DR   SignaLink; Q00796; -.
DR   BioGRID-ORCS; 6652; 15 hits in 1077 CRISPR screens.
DR   ChiTaRS; SORD; human.
DR   EvolutionaryTrace; Q00796; -.
DR   GeneWiki; SORD; -.
DR   GenomeRNAi; 6652; -.
DR   Pharos; Q00796; Tchem.
DR   PRO; PR:Q00796; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q00796; protein.
DR   Bgee; ENSG00000140263; Expressed in right lobe of thyroid gland and 126 other tissues.
DR   ExpressionAtlas; Q00796; baseline and differential.
DR   Genevisible; Q00796; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031514; C:motile cilium; ISS:UniProtKB.
DR   GO; GO:0000721; F:(R,R)-butanediol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0030246; F:carbohydrate binding; NAS:UniProtKB.
DR   GO; GO:0047833; F:D-sorbitol dehydrogenase (acceptor) activity; IEA:Ensembl.
DR   GO; GO:0046526; F:D-xylulose reductase activity; IEA:UniProtKB-EC.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003939; F:L-iditol 2-dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IDA:UniProtKB.
DR   GO; GO:0050255; F:ribitol 2-dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0030317; P:flagellated sperm motility; ISS:UniProtKB.
DR   GO; GO:0046370; P:fructose biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; TAS:UniProtKB.
DR   GO; GO:0051160; P:L-xylitol catabolic process; IDA:UniProtKB.
DR   GO; GO:0051164; P:L-xylitol metabolic process; IDA:UniProtKB.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0046688; P:response to copper ion; IEA:Ensembl.
DR   GO; GO:0009725; P:response to hormone; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0006970; P:response to osmotic stress; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0006062; P:sorbitol catabolic process; IDA:UniProtKB.
DR   CDD; cd05285; sorbitol_DH; 1.
DR   InterPro; IPR013149; ADH-like_C.
DR   InterPro; IPR013154; ADH_N.
DR   InterPro; IPR002328; ADH_Zn_CS.
DR   InterPro; IPR011032; GroES-like_sf.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR020843; PKS_ER.
DR   InterPro; IPR045306; SDH-like.
DR   Pfam; PF08240; ADH_N; 1.
DR   Pfam; PF00107; ADH_zinc_N; 1.
DR   SMART; SM00829; PKS_ER; 1.
DR   SUPFAM; SSF50129; SSF50129; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00059; ADH_ZINC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell projection; Cilium;
KW   Direct protein sequencing; Disease variant; Flagellum; Membrane;
KW   Metal-binding; Mitochondrion; NAD; Neuropathy; Oxidoreductase;
KW   Phosphoprotein; Reference proteome; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0000269|PubMed:2691249, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:25944712"
FT   CHAIN           2..357
FT                   /note="Sorbitol dehydrogenase"
FT                   /id="PRO_0000160817"
FT   BINDING         45
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL7, ECO:0007744|PDB:1PL8"
FT   BINDING         51
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P07846"
FT   BINDING         70
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL7, ECO:0007744|PDB:1PL8"
FT   BINDING         71
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL7, ECO:0007744|PDB:1PL8"
FT   BINDING         156
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P07846"
FT   BINDING         184
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL6, ECO:0007744|PDB:1PL8"
FT   BINDING         204
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL6, ECO:0007744|PDB:1PL8"
FT   BINDING         209
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL6, ECO:0007744|PDB:1PL8"
FT   BINDING         273..275
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL6, ECO:0007744|PDB:1PL8"
FT   BINDING         297..299
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:12962626,
FT                   ECO:0007744|PDB:1PL6, ECO:0007744|PDB:1PL8"
FT   BINDING         299
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P07846"
FT   BINDING         300
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P07846"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:25944712"
FT   MOD_RES         211
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         225
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         90..99
FT                   /note="DRVAIEPGAP -> FLTMSPLRKA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056353"
FT   VAR_SEQ         100..356
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056354"
FT   VARIANT         10
FT                   /note="L -> F (in SORDD)"
FT                   /evidence="ECO:0000269|PubMed:32367058"
FT                   /id="VAR_084362"
FT   VARIANT         100..357
FT                   /note="Missing (in SORDD)"
FT                   /evidence="ECO:0000269|PubMed:32367058"
FT                   /id="VAR_084363"
FT   VARIANT         110
FT                   /note="R -> P (in SORDD; results in protein aggregation)"
FT                   /evidence="ECO:0000269|PubMed:32367058,
FT                   ECO:0000269|PubMed:33397963"
FT                   /id="VAR_084364"
FT   VARIANT         135
FT                   /note="H -> R (in SORDD; results in protein aggregation)"
FT                   /evidence="ECO:0000269|PubMed:33397963"
FT                   /id="VAR_084365"
FT   VARIANT         153
FT                   /note="A -> D (in SORDD; unknown pathological significance;
FT                   results in protein aggregation; dbSNP:rs145813597)"
FT                   /evidence="ECO:0000269|PubMed:32367058,
FT                   ECO:0000269|PubMed:33397963"
FT                   /id="VAR_084366"
FT   VARIANT         209..357
FT                   /note="Missing (in SORDD)"
FT                   /evidence="ECO:0000269|PubMed:33314640"
FT                   /id="VAR_084367"
FT   VARIANT         239
FT                   /note="Q -> L (in dbSNP:rs1042079)"
FT                   /evidence="ECO:0000269|PubMed:7782086"
FT                   /id="VAR_000430"
FT   VARIANT         269
FT                   /note="N -> T (in dbSNP:rs930337)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:7782086,
FT                   ECO:0000269|PubMed:8088829, ECO:0000269|PubMed:9183016"
FT                   /id="VAR_060351"
FT   VARIANT         299..357
FT                   /note="Missing (in SORDD)"
FT                   /evidence="ECO:0000269|PubMed:32367058"
FT                   /id="VAR_084368"
FT   VARIANT         322
FT                   /note="V -> I (in SORDD; unknown pathological significance;
FT                   dbSNP:rs149975952)"
FT                   /evidence="ECO:0000269|PubMed:32367058"
FT                   /id="VAR_084369"
FT   CONFLICT        5
FT                   /note="Missing (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        59
FT                   /note="N -> D (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        186
FT                   /note="M -> E (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        281
FT                   /note="T -> S (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        289
FT                   /note="I -> T (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          10..16
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          19..24
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          34..44
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           46..54
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          55..57
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          71..79
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          91..94
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          96..98
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           104..107
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           111..113
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          130..136
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           137..139
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          140..142
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           149..168
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          175..179
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           183..194
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          198..205
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           207..215
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          219..223
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           229..240
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          245..249
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           254..263
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          269..272
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           284..289
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          293..296
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           304..312
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          322..327
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           328..330
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   HELIX           331..339
FT                   /evidence="ECO:0007829|PDB:1PL8"
FT   STRAND          344..349
FT                   /evidence="ECO:0007829|PDB:1PL8"
SQ   SEQUENCE   357 AA;  38325 MW;  FF13DDD5EBE47754 CRC64;
     MAAAAKPNNL SLVVHGPGDL RLENYPIPEP GPNEVLLRMH SVGICGSDVH YWEYGRIGNF
     IVKKPMVLGH EASGTVEKVG SSVKHLKPGD RVAIEPGAPR ENDEFCKMGR YNLSPSIFFC
     ATPPDDGNLC RFYKHNAAFC YKLPDNVTFE EGALIEPLSV GIHACRRGGV TLGHKVLVCG
     AGPIGMVTLL VAKAMGAAQV VVTDLSATRL SKAKEIGADL VLQISKESPQ EIARKVEGQL
     GCKPEVTIEC TGAEASIQAG IYATRSGGNL VLVGLGSEMT TVPLLHAAIR EVDIKGVFRY
     CNTWPVAISM LASKSVNVKP LVTHRFPLEK ALEAFETFKK GLGLKIMLKC DPSDQNP
//
